Brightpath Biotherapeutics (4594) Reports Earnings: Net Sales Down 66.7% YoY, Operating Loss of 547 Million Yen

Brightpath Biotherapeutics (4594) has released its financial results, reporting a 66.7% decrease in net sales compared to the same period of the previous year. On the profit front, the company posted an operating loss of 547 million yen, an ordinary loss of 545 million yen, and a net loss of 530 million yen. Earnings per share (EPS) stood at -3.82 yen.

Regarding the financial structure and metrics, the equity ratio stands at a high 89.8% with zero interest-bearing debt. Meanwhile, the Return on Equity (ROE) was -80.27%, the Return on Assets (ROA) was -70.06%, and retained earnings stood at -5.11 billion yen.